Celldex Therapeutics, Inc. — Director's Dealing 2020

Jun 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2020-06-09

Reporting Person: Martin Samuel Bates (SVP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-09	Common Stock, par value $0.001 per share	P	9750	$3.05	Acquired	10735	Direct

Footnotes

F1: Includes 985 shares of Common Stock acquired under the Company's 2004 Employee Stock Purchase Plan.